RxDoctor Payments Data

Kailash Sharma, MD

Pulmonary Disease · Oak Forest, ILNPI 1407855083

Payments from drug & device makers

$8,811in general payments, 2019–2025

Across 516 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Novo Nordisk$583
  • Sanofi$410
  • Eisai Inc.$401
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$370
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,793100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,811 in reported general payments places this provider in the 70th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois

Medicare billing

Part B allowed, 2024
$449,825
Medicare patients
394
Services billed
5,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab34$164,787
OzempicSemaglutide115$141,316
JardianceEmpagliflozin103$128,641
Trelegy ElliptaFluticasone/Umeclidin/Vilanter138$111,734
FarxigaDapagliflozin Propanediol91$87,448
Breo ElliptaFluticasone/Vilanterol144$72,470
RybelsusSemaglutide50$56,834
MounjaroTirzepatide52$54,476
EliquisApixaban55$52,404
TradjentaLinagliptin51$41,744
Xigduo XrDapaglifloz Propaned/Metformin31$38,889
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$35,398
OxycontinOxycodone Hcl12$30,061
TrulicityDulaglutide29$28,185
LinzessLinaclotide23$21,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$583$198,151165 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$1,492$191,910297 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$224$184,893167 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,666$137,927172 claims
Lilly USA, LLCMounjaro, Trulicity$228$82,66181 claims
PfizerEliquis$36$52,40455 claims
AbbVieLinzess$289$21,61423 claims
MerckBelsomra$12$5,46311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 539 pulmonary disease providers in Illinois.

Other pulmonary disease in Oak Forest

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →